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In recent years in the scientific community, the harmful
effect of a phenolic type of environmental toxicant, known as
bisphenol A (BPA), has achieved great relevance (Fig. 1). The
interest in this compound is increasing owing to its possi-
ble adverse effects on several organs, which has led several
organisations to recommend the prohibition or at least use
reduction, with wide repercussions in the media. BPA has also
aroused interest in  the nephrological community, as  it has
been linked to kidney and endocrine disorders. Since BPA is
cleared by the kidneys, plasma and tissue levels of BPA are
markedly increased in patients with impaired renal function.
But what is  bisphenol A and why does it arouse such inter-
est? The significance of BPA stems from its ubiquity, because
it is a compound that is  found in the  most commonly used
plastic containers (polycarbonates) and epoxy resins in pack-
aging. BPA is  released from these plastic containers and it
is absorbed by humans that consume food or liquid that
is being stored in these containers. BPA was  synthesised in
the 1930s as a synthetic oestrogen,1 and was subsequently
replaced by diethylstilbestrol.2 It is converted into a  monomer
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during the manufacture of various commonly used products,
such as plastic bottles, baby bottles or contact lenses. BPA-
containing epoxy resins are used as a coating in cans used
for food, although there is  now a tendency to be substituted
by  polyesters.3 Given the widespread use of BPA, its potential
risk to human health as a  synthetic oestrogen for daily con-
sumption has  been a  topic of debate in regulatory agencies for
many years.
BPA generally passes into the  bloodstream through the oral
route, usually accompanying the products contained in the
plastic containers. It is immediately absorbed (5–20 min) and
has a  bioavailability greater than 70%.4,5 As  with phenols pro-
duced by gut bacteria, BPA is  conjugated in the intestine and
liver with glucuronic acid and is  eliminated almost exclusively
in the urine.6 Exposure in ways other than the oral route may
also occur, and so it is  considered an environmental toxic,
e.g. by inhalation (this may  cause cough, asthmatic attacks
and bronchospasms); eye exposure (causing swelling around
the eyes, facial pruritus and conjunctivitis) or skin exposure
(redness and roughness).
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Fig. 1 – Chemical structure of the bisphenol A monomer.
Molecular mass: 284 Da.
However, more  controversial is its role as an endocrine ago-
nist after prolonged constant exposure for many years. BPA
is commonly referred to as  an endocrine “disruptor”. Despite
the evidence published,7 the European and American author-
ities consider that, because it  is eliminated rapidly, BPA may
be considered as a  relatively safe compound. Daily oral and
cutaneous exposure to bisphenol has recently been estimated
to be 0.2–0.3 mg  BPA g/kg of weight.8
In the absence of conclusive scientific evidence, it is
recommended to  reduce exposure as much as possible,9
with maximum safety levels of 5 mg/kg/day in adults. How-
ever, following a  precautionary principle, baby bottles and
rubber nipples were banned throughout the EU from June
2011 onwards, since much greater potential harm has been
observed in newborns.
The reasons why a  more  widespread ban has not been
imposed are based on the following:
• High economic cost of completely eliminating the contain-
ers currently used.
• The strongest evidence has been seen in animals, with
limited information of toxicity in humans.
• Differences in the metabolism between laboratory animals
and humans.
• Complete renal elimination immediately after ingestion.
However, other authors support the elimination of its
industrial use due to the increasing amount of evidence on
the association of BPA exposure with the  development of dis-
eases, both in laboratory animals and based on observational
studies in humans.
Evidence  in  animal  testing
There are direct data on BPA’s toxicity in laboratory animals.
They include the following:
a) Effects on the reproductive system: In rats given high doses
of BPA there is an increase in immature spermatozoa.10
The effects of BPA exposure in neonatal mice was  differ-
ent depending on the amount of BPA administered. At
2 mg/kg, the weight of an adult prostate increases11 and
at  10 mg/kg, prostate development stops.12 In adult male
rats, a dose of 10 mg/kg increases the susceptibility of the
prostate gland to develop hormonal carcinogenesis10 and
sperm counts and testosterone levels are reduced, with a
significant impact on fertility.13
b) Neurological effects:  A study of developing zebrafish embryos
showed that BPA may  influence brain development, includ-
ing the hypothalamus, telencephalon and preoptic area.14
Studies in rodents showed that perinatal or uterine-related
BPA exposure can cause permanent changes in behaviour,
including increased levels of aggression and anxiety, and
changes in learning, memory,  searching and emotional
responsiveness.15 Several studies with mice concluded
that exposure to low doses of maternal BPA has  long-
term consequences on neurobehavioural development.16
Also, neonatal BPA exposure may  affect brain mor-
phology, with sexual dimorphism and adult neuronal
phenotypes.17
c) Effects on  weight: Continued BPA exposure has lasting effects
on body weight and adiposity.18 One study performed on
rats showed that perinatal exposure to drinking water
with 1 mg/L of BPA increased adipogenesis in  females at
weaning.19
Evidence  in  humans
Many of the findings observed in laboratory animals have been
confirmed in clinical studies.
a) Reproductive system and endocrine disorders. It  has been
observed that even very low concentrations of BPA
are capable of producing changes in  spermatogenesis20
and oestrogen production,21 pancreatic damage,22 thyroid
problems23 or liver damage.24
b)  Tumourigenesis.  BPA exposure has been associated with the
appearance of neuroblastomas and breast tumours.25
c) Neurological effects. In a  subgroup of young children, pre-
natal BPA exposure may be associated with an increase in
hyperactivity and aggressiveness.26
d) Obesity and diabetes. BPA exposure has been associ-
ated with the  onset of obesity,27 insulin resistance
and diabetes,14,28,29 and BPA inhibits the release of
adiponectin.30
e) Cardiovascular disease. In recent years, numerous studies
have related this compound with various abnormalities in
the cardiovascular system, such as  arrhythmias, by binding
to calcium channels,31 and an increase in cardiovascular
risk. For  every increase of 4.5 mg/L of BPA in urine, the
increase in the incidence of coronary disease goes up by
13% over a  10 years’ time.32 But it cannot be ruled out that
this increase may  be  due to other cause since that the  neg-
ative effect of BPA was lost after adjusting for traditional
cardiovascular risk factors. it is likely that blood pressure
is influenced by BPA. In healthy adults in  the  United States,
urinary BPA levels greater than 4 g/L have been associated
with a  50% increase in the  prevalence of hypertension as
compared with urinary BPA levels <1.5 mg/L.33 Recently, the
relationship between BPA and vascular damage has been
reviewed by Bosch et al.34 Table 1 summarises some of the
most relevant articles.
Role  of  BPA in  kidney  disease
The relationship of BPA to kidney disease merits a  separate
chapter, given that, in  this case, not only is  it a  compound
that plays a direct role  in kidney damage, but it is also
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Table 1 – Cardiovascular effects of BPA.
Metabolic syndrome Vasiliu, Epidemiology, 200627
Obesity and insulin
resistance
Wang,  J  Clin Endocrinol Metab,
201250
Atherosclerosis Lind et al., Atherosclerosis,
2011
Coronary heart disease Melzer et al., Circulation,
201229
Hypertension Shankar et al., J  Environ Public
Health, 201230
cleared mainly in urine; therefore it accumulates in these
patients.
The greater the decrease in glomerular filtration, the lower
the rate of elimination of BPA in urine. Thus, patients on
haemodialysis are not able to clear BPA,35 and there is a
strong correlation between BPA accumulation and impaired
renal function.36 However, the  2003–2006 National Health and
Nutrition Examination Survey (NHANES III), with a sample
of 2573 patients, also found a decrease in the elimination of
BPA in relation to the level of impairment in renal function,
although it was only significant in  women.37 Only few stud-
ies have measured the plasma concentration of BPA in renal
patients; Krieter et al.38 observed a correlation between the
impairment in renal function and plasma concentrations of
BPA, regardless of gender. In CKD stages 1–2, the levels are
similar to healthy controls and below the levels of detection
used  (<0.2 ng/mL), and in stages 3–4 patients the levels of
BPA rise sharply, to 0.7 ±  1.0 ng/mL. In stage G5 the values are
up to 1.6 ± 1.8 ng/mL (p < 0.05), while in G5D the values were
10.0 ± 6.6 ng/mL. Although it is known that chronic kidney
disease decreases urinary excretion, the pharmacokinetics,
bioavailability and tissue accumulation in humans are not
known.
Among the evidence that points to  a  possible causal
role in kidney disease is the  fact that in healthy adults,
urinary BPA levels >1.4 mg/L are associated with a  23%
higher risk of microalbuminuria than in adults with levels
<0.5 mg/L37 and in children.39 It has also been associated with
low-grade albuminuria in  Chinese adults.40 The suggested
possible mechanisms of BPA-mediated nephrotoxicity include
increased oxidative stress, inflammation and induction of
hypertension.41,42
It has also recently been reported that serum BPA may  be a
predictor of kidney disease progression in  patients with Type
2 Diabetes,43 such that patients with elevated plasma levels
of BPA experience greater kidney disease progression. Table 2
lists the principal publications that relate BPA exposure and
kidney damage.
However, it is the accumulation of this substance in
patients with decreased glomerular filtration that has moti-
vated the analysis of the compound as  a  possible uraemic
toxin.44 One of the arguments put forward by the  various
Official Agencies for considering the use of BPA in ordinary
consumption to be safe is its almost complete elimination in
urine as a  conjugated compound.45 Therefore, patients with
kidney damage, in whom elimination is impaired, should be
considered a population especially susceptible of the potential
adverse effects of BPA exposure.
BPA  in  patients  on  dialysis
Patients on haemodialysis are particularly susceptible to the
risk of toxicity due to  BPA, as renal elimination is com-
pletely impaired. This is  further exacerbated in patients on
haemodialysis, since BPA, being a ubiquitous component, is
part of the composition of the plastic material of some dial-
ysers and commonly used dialysis systems, in  the form of
polycarbonate in  the casings and in  multiple dialysis mem-
branes, such as  polysulfone (PS) or polyester-polymer alloy
(PEPA).
In these dialysers, the  polymer is in  constant contact with
the blood and it may  be  released into the circulatory system, so
that the  increase of BPA in haemodialysis patients may  be due
not only to  environmental exposure, but possibly also to the
method itself.46 Several studies have reported that effluents
from dialysers made of these materials have higher concentra-
tions of BPA,36,44,45 with increased BPA migration when blood
is used instead of saline.46 Therefore, in these patients it is
very difficult to determine whether the plasma concentrations
exceed recommended levels.
Despite all this information, there are practically no long-
term prospective studies that relate haemodialysis to the
presence of BPA and its possible effects. In 2013, Krieter et  al.38
studied the effect of haemodialysis on BPA over a  4-week
period and concluded that the differences between mem-
branes with bisphenol (polysulfone) and without bisphenol
(polynephron) were not significant. However, the fact that the
casings of all the dialysers used contained BPA and the short
duration of the study might explain that the values of BPA were
not different.
To evaluate this discrepancy between in vitro studies or
studies in a single session and Krieter’s results, we have
recently published (Bosch-panadero et al.47) a longer-term
study (3 months); this is  a  crossover study of 69  patients,
comparing dialysers with BPA (polysulfone) and without
BPA (polynephron), we found that serum and intracellu-
lar levels of BPA increased with the use of polysulfone
(48.8 ±  6.8 to  69.1 ± 10.1 ng/mL), and decreased with dialy-
sis with polynephron (70.6 ± 8.4 to 47.1 ± 7.5 ng/mL; p < 0.05).
The increase in  BPA were associated with elevated levels of
intracellular free radicals and circulating inflammatory mark-
ers (IL-6, TNF-, C-reactive protein). It was also observed in
in vitro experiments using circulating cells that BPA polysul-
fone membranes released bisphenol into the culture medium
and resulted in the increased production of cytokines in  lym-
phocytes in  culture.47
Regarding haemodiafiltration, there are currently no well-
designed studies to determine the effect of this technique on
the elimination of BPA. Although it would be expected bet-
ter elimination with haemodiafiltration, the reinfusion of fluid
used circulates by BPA membranes, which may  increased the
infusion of BPA.
Lastly, in  the case of peritoneal dialysis, there is only one
study that looks at the  impact of BPA, which found that its con-
centration in dialysis fluid is well below the permitted value.
Although only 4 patients were studied, levels only seemed to
increase in one of them, so the authors conclude that BPA does
not appear to be reduced or increased by peritoneal dialysis.48
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Table 2 – Significance of bisphenol A in nephrology. Main publications relating the effects of BPA on the kidneys,
impaired elimination or  its relation to  dialysis.
BPA in  urine and microalbuminuria Urinary BPA >  1.4 mg/L: A  23% increase in
albuminuria
Li  et al., Kidney Int, 201440
BPA in  urine and microalbuminuria in
children
Increase of  0.28 mg/g and MA per unit of  urinary
BPA
Transande et al., Kidney Int, 201339
BPA podocytopathy in laboratory animals BPA ip 50  mg/kg induces proteinuria, glomerular
hyperfiltration and podocytopenia
Olea-Herrera et al., Cell Physiol,
201441
BPA and hypertension The NHANES study found a correlation between
BPA and HTN
Shankar et al., J  Environ Public
Health, 201233
BPA and progression of type 2 DM Serum BPA correlates negatively with GF (OR:
6.65)
Hu et al., Acta Diabetológica,
201543
BPA and renal function Serum BPA: inverse correlation with GF Krieter et al., Artif Organs, 201338
Serum BPA increases in HD  15 patients on  HD saw elevated BPA with PS Murakami et al., Blood Purif, 200736
Serum BPA is  affected by the  type of  dialyser In 69 patients on HD  (crossover study), BPA
increased with PS and decreased with PN
Bosch, J  Am Soc Nephrol, 201547
Serum BPA was associated with
inflammation and oxidation in HD
BPA and dialyser fibres with BPA increased
inflammation and oxidation in mononuclear
cells
Bosch, J  Am Soc Nephrol, 201547
GF: glomerular filtration; HD: haemodialysis; MA: microalbuminuria; PN:  polynephron; PS: polysulfone; Urinary BPA: bisphenol in urine.
Some  considerations  regarding  bisphenol  in
nephrology
Can BPA be considered an uraemic toxin? Do serum and tis-
sue levels increase in chronic kidney disease? We  know that
patients with kidney disease have elevated serum levels of
BPA and that some of the effects of BPA in  laboratory ani-
mals also appear in uraemic patients on haemodialysis, but
it is not known whether there is a  direct relationship. It is  not
yet known whether removing BPA from the material and the
solutions will solve signs and symptoms associated to BPA.
Our study47 showed how the use of membranes with BPA
increases serum and intracellular levels of BPA in haemodial-
ysis patients. There was no correlation with time on dialysis,
and there was also high variability among the different indi-
viduals, which may  suggest that there the  metabolisation
process is not uniform in all patients. BPA may  be  responsible,
at least in part, for the increase in  the inflammatory markers
and oxidation observed in these patients. However, it seems
appropriate, as recommended by FDA in other situations, to
attempt to reduce BPA exposure as much as possible, as it
seems likely that it may  be considered to  be an exogenous
uraemic toxin with possible clinical implications.
Recent evidence has led the  Scientific Committee on
Emerging and Newly  Identified Health Risks commissioned
by the European Union to  issue in early 2015 a  report enti-
tled “Final opinion on the  safety of the use of bisphenol A
in medical devices”, in which they conclude that there is
a risk of adverse effects from BPA when it is “available for
systemic exposure after non-oral exposure routes, especially
for neonates in intensive care units, infants undergoing pro-
longed medical procedures and for dialysis patients”,49 and
they therefore recommend limiting its use whenever possi-
ble and emphasise that the beneficial effects of the material
used (rigidity, durability, etc.) do not exceed the potential risk
of BPA.
The decrease in  the urinary elimination of BPA in patients
with chronic kidney disease, in  the stages before dialysis,
should lead to specific studies to determine whether this pop-
ulation should be  considered, together with newborns, as  an
at-risk population in  terms of environmental exposure to  this
compound.
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